AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$LFST

LifeStance (LFST) Q3 2026 Earnings Call Transcript

LifeStance (LFST) reported Q3 2026 revenue growth of 25% to $456M, driven by increased visit volumes and higher revenue per visit. The company expanded its clinician base by 11% and opened 8 new centers. It also raised full-year revenue guidance to $1.741B-$1.761B. LifeStance highlighted strong results in specialty services for treatment-resistant depression and plans to invest in strategic priorities. The company expects temporary revenue growth impact in 2027 due to EHR implementation.

Original reporting
finance.yahoo.com
Published Nov 5, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
LifeStance (LFST) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$LFSTBullishHigh
01

Why it matters

Earnings beat and guidance raise suggest upside; however, a temporary EHR implementation headwind may limit near‑term growth.

02

Market read

First‑time disclosure of earnings and guidance provides fresh trading catalyst for LFST.

03

What to watch

Potential short‑term margin pressure from the upcoming EHR rollout in 2027.

Relevance 8/10Novelty 8/10Timing: post‑earnings release today

Background

LifeStance reported Q3 2026 results, highlighted clinic productivity, acquisitions, specialty service expansion, and updated full‑year guidance.

Company-level read

Ticker impact

$LFSTBullishHigh confidence
Context

Q3 earnings released with revenue of $456M, 25% growth and raised full-year guidance to $1.741‑$1.761B.

Expected impact

upward pressure as market prices in stronger revenue and margin outlook

Evidence & confidence

Revenue beat and raised guidance are fresh, material data that can move the stock immediately.

Market effects

Sector

Strong performance may lift the mental‑health services sector and related health‑tech stocks.

Regional

Positive for U.S. healthcare providers expanding via acquisitions.

Global

Limited to U.S. mental‑health market; minimal global spillover.

Counterpoint

What could challenge this read

EHR transition risk could temper growth; investors may wait for post‑implementation results.

Key entities

  • Company
    LifeStance Health

    U.S. mental‑health services provider (ticker LFST).

Read at source← All news

StoryLifeStance Health posts strong Q3 2026 results and lifts full‑year outlook

Also covered by

4 outlets

Related articles

$LFSTMed

BMO raises Lifestance Health stock price target on strong results

BMO Capital raised its price target on Lifestance Health (LFST) to $16.00, citing strong Q3 results. Revenue beat estimates by 5.6%, and EBITDA exceeded by 23.6%. The company raised its full-year outlook, but expects a sequential EBITDA decline due to reinvestment. LFST trades at $13.43 with a $5.1B market cap. The company also announced Q3 2026 earnings, surpassing expectations with a 25% revenue increase.

investing.com
$LFSTMed

What LifeStance Health Group (LFST) Said on Its Q3 Earnings Call

LifeStance Health Group (LFST) forecasted Q4 revenue of $446M-$466M and adjusted EBITDA of $56M-$64M. The company expects a 1-2% reduction in 2027 revenue growth due to a new electronic health record system. LifeStance expanded specialty services, including TMS and SPRAVATO, and plans to continue acquisitions and center openings. Management expects specialty services revenue to reach $70M this year, up from $50M in 2025.

finance.yahoo.com
$LFSTMed

LifeStance Health Group Inc (LFST) (Q3 2026) Earnings Call Highlights: Revenue Jumps 25%

LifeStance Health (LFST) reported 25% revenue growth in Q3 2026. The company expects EHR implementation to reduce 2027 revenue growth by 1-2% and cost $20-30M. Clinician retention is stable, but new clinician retention is low. Q4 adjusted EBITDA guidance suggests a sequential decline due to planned investments. Specialty services, including Spravato, are growing but face variable payer reimbursement. Management remains optimistic about long-term margin expansion and clinician growth.

finance.yahoo.com
$LFSTMed

LifeStance Health: Q3 Earnings Snapshot

LifeStance Health Group Inc. (LFST) reported Q3 net income of $22.4M, or 6 cents per share, beating estimates. Revenue was $455.9M, also exceeding forecasts. The company expects Q4 revenue of $446M-$466M and full-year revenue of $1.74B-$1.76B.

finance.yahoo.com